Galectin Therapeutics
Presence
Galectin Therapeutics is a company listed under the stock ticker GALT (US).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Galectin Therapeutics
- Joel Lewis, President, Chief Executive Officer and Director
- Kary Eldred, Director
- Richard Uihlein, Chairman of the Board
Popular executive movements at Galectin Therapeutics
- Khurram Jamil has joined the company as Vice President, Clinical Development (posted on March 13 2024).
- Benjamin Carson has joined the company as Director (posted on October 12 2023).
Create your alert
to follow the executive moves at Galectin Therapeutics.
Biotechnology
Galectin Therapeutics has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Galectin Therapeutics
- Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022 | Galectin Therapeutics Inc.
- Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress | Galectin Therapeutics Inc.
- Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer | Galectin Therapeutics Inc.
- Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- View more press releases Close
Social media about Galectin Therapeutics
- Galectin Therapeutics on Wikipedia, Google News & Yahoo Finance
- Galectin Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Gilbert Amelio 
Call Galectin Therapeutics at +1 678...
